Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $644,824.80 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 34,668 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $18.60, for a total value of $644,824.80. Following the completion of the transaction, the insider directly owned 1,187,644 shares of the company’s stock, valued at approximately $22,090,178.40. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Adaptive Biotechnologies Stock Down 4.3%

Shares of Adaptive Biotechnologies stock opened at $15.77 on Friday. Adaptive Biotechnologies Corporation has a 12-month low of $6.26 and a 12-month high of $20.76. The company has a market capitalization of $2.41 billion, a price-to-earnings ratio of -39.42 and a beta of 2.18. The firm’s 50-day moving average price is $17.03 and its two-hundred day moving average price is $15.20.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The company had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 48.73%. The firm’s quarterly revenue was up 51.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.23) EPS. On average, sell-side analysts expect that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ADPT. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Morgan Stanley initiated coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price target on the stock. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday. Finally, JPMorgan Chase & Co. increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $17.56.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ADPT. EverSource Wealth Advisors LLC boosted its position in Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after buying an additional 1,565 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of Adaptive Biotechnologies by 693.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 13,796 shares of the company’s stock worth $224,000 after purchasing an additional 12,058 shares during the period. ProShare Advisors LLC grew its stake in shares of Adaptive Biotechnologies by 9.9% in the fourth quarter. ProShare Advisors LLC now owns 34,057 shares of the company’s stock worth $553,000 after purchasing an additional 3,078 shares during the last quarter. Sigma Planning Corp increased its holdings in Adaptive Biotechnologies by 150.1% in the fourth quarter. Sigma Planning Corp now owns 32,550 shares of the company’s stock valued at $529,000 after purchasing an additional 19,535 shares during the period. Finally, Jennison Associates LLC raised its position in Adaptive Biotechnologies by 103.9% during the 4th quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock worth $43,437,000 after purchasing an additional 1,363,181 shares during the last quarter. Institutional investors own 99.17% of the company’s stock.

Trending Headlines about Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results beat expectations — ADPT reported a $0.09 loss per share vs. a $0.19 consensus loss and revenue of $71.7M (up 51% YoY), which investors typically view as positive for growth outlook. Read More.
• Positive Sentiment: Analyst upgrade/target increase — JPMorgan raised its price target to $21 and maintained an overweight stance, implying meaningful upside versus recent levels and likely supporting buying interest. Read More.
• Neutral Sentiment: Multiple analyst write-ups and coverage: Zacks and other outlets published detail and comparisons to estimates; consensus remains a “Moderate Buy” with an average price target near the mid‑teens to low‑$20s — useful context but not a single catalyst. Read More.
• Neutral Sentiment: Full earnings materials and transcript are available for deeper review (management commentary and slide deck will guide whether revenue quality and guidance justify the rally). Read More.
• Negative Sentiment: Significant insider selling disclosed this week — CEO Chad M. Robins and other insiders sold large blocks (CEO ~125k shares; other insider sales also reported). Large insider sales can pressure sentiment even when results are strong. Read More.
• Negative Sentiment: Company remains unprofitable with negative margins and a negative ROE; analysts still expect a full-year loss (consensus EPS negative), which leaves valuation and timing of profitability as ongoing investor concerns. Read More.
• Neutral Sentiment: Reported short-interest data in this batch is effectively zero/unchanged and shows no immediate short‑squeeze dynamics; days‑to‑cover computed as 0.0, so short interest is not a current market driver. (Item flagged in recent data feeds.)

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.